TARGETED THERAPY FOR SYSTEMIC LUPUS ERYTHEMATOSUS: PRESENT AND FUTURE
DOI: https://doi.org/10.29296/25877305-2021-11-03
Issue:
11
Year:
2021
Systemic lupus erythematosus (SLE) is an autoimmune systemic disease, the pathogenesis of which is
based on defects in immunoregulation, leading to uncontrolled hyperproduction of autoantibodies to the
components of their own tissues and the development of chronic inflammation affecting many organs and
systems. The close interest in SLE over the past decades has allowed us to improve the methods of diagnosing
the disease, but the management of patients continues to be a difficult task. The development of treatment
methods is hampered primarily by the unknown etiology of the disease, the large variability of clinical
manifestations, the possibility of both long-term spontaneous remissions and malignant, rapidly progressing,
sometimes lightning-fast course. To control the disease, almost the entire arsenal of anti-inflammatory and
cytotoxic drugs existing in medicine is currently used, the use of which has significantly improved the
prognosis of patients lives. Current treatments aim to suppress autoimmune inflammation, prevent relapses,
and reduce clinical symptoms in order to prevent permanent organ damage. This review highlights the immune
mechanisms that prevail in new targeted treatments for SLE.
Keywords:
therapy
systemic lupus erythematosus
clinical studies
monoclonal antibodies
eculizumab
rituximab
belimumab
obintuzumab
tabalumab
ataxicept
bortezomib
anifrolumab
sifalimumab
rontalizumab
References:
- Kozlov V.A., Savchenko A.A., Kudrjavtsev I.V. i dr. Klinicheskaja immunologija. Krasnojarsk: Polikor, 2020; 386 s. [Kozlov V.A., Savchenko A.A., Kudryavtsev I.V. et al. Klinicheskaya immunologiya. Krasnoyarsk: Polikor, 2020; 386 s. (in Russ.)]. DOI: 10.17513/np.438
- Alexander T., Cheng Q., Klotsche J. et al. Proteasome inhibition with bortezomib induces a therapeutically relevant depletion of plasma cells in SLE but does not target their precursors. Eur J Immunol. 2018; 48: 1573–9. DOI: 10.1002/eji.201847492
- Alshaiki F., Obaid E., Almuallim A. et al. Outcomes of rituximab therapy in refractory lupus: a meta-analysis. Eur J Rheumatol. 2018; 5: 118–26. DOI: 10.5152/eurjrheum.2018.17096
- Aranow C., Dall’Era M., Byron M. et al. FRI0305 Phase 2 trial of induction therapy with anti-cd20 (RITUXIMAB) followed by maintenance therapy with anti-baff (BELIMUMAB) in patients with active lupus nephritis. Ann Rheum Dis. 2018; 77: 690.
- Banchereau R., Hong S., Cantarel B. et al. Personalized Immunomonitoring Uncovers Molecular Networks that Stratify Lupus Patients. Cell. 2016; 165 (3): 551–65. DOI: 10.1016/j.cell.2016.03.008
- Buyon J.P., Cohen P., Merrill J.T. et al. A highlight from the LUPUS 2014 meeting: eight great ideas. Lupus Sci Med. 2015; 2 (1): e000087. DOI: 10.1136/lupus-2015-000087
- Collins C.E., Dall’Era M., Kan H. et al. Response to belimumab among patients with systemic lupus erythematosus in clinical practice settings: 24-month results from the OBSErve study in the USA. Lupus Sci Med. 2016; 3 (1): e000118. DOI: 10.1136/lupus-2015-000118
- Clowse M.E., Wallace D.J., Furie R.A. et al. Efficacy and safety of epratuzumab in moderately to severely active systemic lupus erythematosus: results from two phase III randomized, double-blind, placebo-controlled trials. Arthritis Rheumatol. 2017; 69: 362–75. DOI: 10.1002/art.39856
- D’Cruz D., Maksimowicz-McKinnon K., Oates J. et al. Efficacy and safety of belimumab in patients of black race with systemic lupus erythematosus: results from the EMBRACE study. Lupus Sci Med. 2019; 6: A149–A150. DOI: 10.1136/lupus-2019-lsm.200
- Doria A., Stohl W., Schwarting A. et al. Efficacy and safety of subcutaneous belimumab in anti-double-stranded DNA-positive, cypocomplementemic patients with systemic lupus erythematosus. Arthritis Rheumatol. 2018; 70 (8): 1256–64. DOI: 10.1002/art.40511
- Dorner T., Shock A., Goldenberg D.M. et al. The mechanistic impact of CD22 engagement with epratuzumab on B cell function: Implications for the treatment of systemic lupus erythematosus. Autoimmun Rev. 2015; 14: 1079–86. DOI: 10.1016/j.autrev.2015.07.013
- Ehrenstein M.R., Wing C. The BAFFling effects of rituximab in lupus: danger ahead? Nat Rev Rheumatol. 2016; 12 (6): 367–72. DOI: 10.1038/nrrheum.2016.18
- Everly M.J., Everly J.J., Susskind B. et al. Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. Transplantation. 2008; 86 (12): 1754–61. DOI: 10.1097/TP.0b013e318190af83
- Fanouriakis A., Kostopoulou M., Alunno A. et al. 2019 Update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019; 78 (6): 736–45. DOI: 10.1136/annrheumdis-2019-215089
- Fanouriakis A., Kostopoulou M., Cheema K. et al. 2019 Update of the joint European league against rheumatism and european renal association-european dialysis and transplant association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis. 2020; 79 (6): 713–23. DOI: 10.1136/annrheumdis-2020-216924
- Furie R., Aroca G., Alvarez A. et al. A phase II randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of obinutuzumab or placebo in combination with mycophenolate mofetil in patients with active class III or IV lupus nephritis. Arthritis Rheumatol. 2019; 71 (10): 9–39.
- Furie R.A., Leon G., Thomas M. et al. A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study. Ann Rheum Dis. 2015; 74 (9): 1667–75. DOI: 10.1136/annrheumdis-2013-205144
- Furie R., Merrill J., Werth V. et al. Anifrolumab, an anti-interferon alpha receptor monoclonal antibody, in moderate to severe systemic lupus erythematosus. Arthritis Rheumatol. 2015; 67: 3223. DOI: 10.1002/art.39962
- Furie R.A., Morand E.F., Bruce I.N. et al. Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial. Lancet Rheumatol. 2019; 208–19. DOI: 10.1016/S2665-9913(19)30076-1
- GlaxoSmithKline. GSK Announces Positive Headline Results in Phase 3 Study of Benlysta in Patients with Lupus Nephritis, 2019. Available online at: https://www.gsk.com/en-gb/media/press-releases/gsk-announces-positive-headline-results-in-phase-3-study-of-benlysta-in-patients-with-lupus-nephritis
- Gomez Mendez L.M., Cascino M.D., Garg J. et al. Peripheral blood B cell depletion after rituximab and complete response in lupus nephritis. Clin J Am Soc Nephrol. 2018; 13 (10): 1502–9. DOI: 10.2215/CJN.01070118
- Greenbaum L.A., Fila M., Ardissino G. et al. Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome. Kidney Int. 2016; 89 (3): 701–11. DOI: 10.1016/j.kint.2015.11.026
- Hennessey A., Lukawska J., Cambridge G. et al. Advers infusion reactions to rituximab in systemic lupus erythematosus: a retrospective analysis. BMC Rheumatol. 2019; 3: 32. DOI: 10.1186/s41927-019-0082-7
- Houssiau F.A., Doria A. Targeting BAFF/BLyS in lupus: is the glass half-full or half-empty? Ann Rheum Dis. 2016; 75 (2): 321–2. DOI: 10.1136/annrheumdis-2015-208312
- Iaccarino L., Bettio S., Reggia R. et al. Effects of belimumab on flare rate and expected damage progression in patients with active systemic lupus erythematosus. Arthritis Care Res. 2017; 69 (1): 115–23. DOI: 10.1002/acr.22971
- Isenberg D.A., Petri M., Kalunian K. et al. Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2016; 75 (2): 323–31. DOI: 10.1136/annrheumdis-2015-207653
- Ishii T., Tanaka Y., Kawakami A. et al. Multicenter double-blind randomized controlled trial to evaluate the effectiveness and safety of bortezomib as a treatment for refractory systemic lupus erythematosus. Mod Rheumatol. 2018; 28 (6): 986–92. DOI: 10.1080/14397595.2018.1432331
- Jones A., Muller P., Dore C.J. et al. Belimumab after B cell depletion therapy in patients with systemic lupus erythematosus (BEAT Lupus) protocol: a prospective multicentre, double-blind, randomised, placebo-controlled, 52-week phase II clinical trial. BMJ Open. 2019; 9 (12): e032569. DOI: 10.1136/bmjopen-2019-032569
- Kalunian K.C., Merrill J.T., Maciuca R. et al. A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-alpha) in patients with systemic lupus erythematosus (ROSE). Ann Rheum Dis. 2016; 75 (1): 196–202. DOI: 10.1136/annrheumdis-2014-206090
- Kalunian K.C., Merrill J.T., Maciuca R. et al. A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-alpha) in patients with systemic lupus erythematosus (ROSE). Ann Rheum Dis. 2016; 75 (1): 196–202. DOI: 10.1136/annrheumdis-2014-206090
- Kansal R., Richardson N., Neeli I. et al. Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus. Sci Transl Med. 2019; 11 (482): eaav1648. DOI: 10.1126/scitranslmed.aav1648
- Khamashta M., Merrill J.T., Werth V.P. et al. Sifalimumab, an anti-interferon-alpha monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2016; 75 (11): 1909–16. DOI: 10.1136/annrheumdis-2015-208562
- Kraaij T., Kamerling S.W.A., de Rooij E.N.M. et al. The NET-effect of combining rituximab with belimumab in severe systemic lupus erythematosus. J Autoimmun. 2018; 91: 45–54. DOI: 10.1016/j.jaut.2018.03.003
- Kavanagh D., Smith-Jackson K. Eculizumab in children with hemolytic uremic syndrome. Kidney Int. 2016; 89 (3): 537–8. DOI: 10.1016/j.kint.2015.12.039
- Licht C., Greenbaum L.A., Muus P. et al. Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. Kidney Int. 2015; 87 (5): 1061–73. DOI: 10.1038/ki.2014.423
- Masoud S., McAdoo S.P., Bedi R. et al. Ofatumumab for B cell depletion in patients with systemic lupus erythematosus who are allergic to rituximab. Rheumatology. 2018; 57 (7): 1156–61. DOI: 10.1093/rheumatology/key042
- Merrill J.T., Shanahan W.R., Scheinberg M. et al. Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2018; 77 (6): 883–9. DOI: 10.1136/annrheumdis-2018-213032
- Merrill J.T., van Vollenhoven R.F., Buyon J.P. et al. Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2016; 75 (2): 332–40. DOI: 10.1136/annrheumdis-2015-207654
- Morand E.F., Furie R., Tanaka Y. et al. Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med. 2020; 382 (3): 211–21. DOI: 10.1056/NEJMoa1912196
- Murphy G., Isenberg D.A. New therapies for systemic lupus erythematosus – past imperfect, future tense. Nat Rev Rheumatol. 2019; 15 (7): 403–12. DOI: 10.1038/s41584-019-0235-5
- Parodis I., Soder F., Faustini F. et al. Rituximab-mediated late-onset neutropenia in systemic lupus erythematosus – distinct roles of BAFF and APRIL. Lupus. 2018; 27 (9): 1470–8. DOI: 10.1177/0961203318777116
- Parodis I., Sjowall C., Jonsen A. et al. Smoking and pre-existing organ damage reduce the efficacy of belimumab in systemic lupus erythematosus. Autoimmun Rev. 2017; 16 (4): 343–51. DOI: 10.1016/j.autrev.2017.02.005
- Parodis I., Gomez A., Frodlund M. et al. Smoking reduces the efficacy of belimumab in mucocutaneous lupus. Expert Opin Biol Ther. 2018; 18 (8): 911–20. DOI: 10.1080/14712598.2018.1494719
- Parodis I., Johansson P., Gomez A. et al. Predictors of low disease activity and clinical remission following belimumab treatment in systemic lupus erythematosus. Rheumatology. 2019; 58 (12): 2170–76. DOI: 10.1093/rheumatology/kez191
- Parodis I., Gomez A., Emamikia S. et al. Established organ damage reduces belimumab efficacy in systemic lupus erythematosus. Ann Rheum Dis. 2019; 78 (7): 1006–7. DOI: 10.1136/annrheumdis-2018-214880
- Parodis I., Åkerström E., Sjöwall C. et al. Autoantibody and cytokine profiles during treatment with belimumab in patients with systemic lupus erythematosus. Int J Mol Sci. 2020; 21 (10): 3463. DOI: 10.3390/ijms21103463
- Ramskold D., Parodis .I, Lakshmikanth T. et al. B cell alterations during BAFF inhibition with belimumab in SLE. EBioMedicine. 2019; 40: 517–27. DOI: 10.1016/j.ebiom.2018.12.035
- Reddy V., Dahal L.N., Cragg M.S. et al. Optimising Bcell depletion in autoimmune disease: is obinutuzumab the answer? Drug Discov Today. 2016; 21 (8): 1330–8. DOI: 10.1016/j.drudis.2016.06.009
- Scheinberg M.A., Hislop C.M., Martin R.S. Blisibimod for treatment of systemic lupus erythematosus: with trials you become wiser. Expert Opin Biol Ther. 2016; 16 (5): 723–33. DOI: 10.1517/14712598.2016.1169270
- Schweighoffer E., Tybulewicz V.L. Signalling for B cell survival. Curr Opin Cell Biol. 2018; 51: 8–14. DOI: 10.1016/j.ceb.2017.10.002
- Stohl W., Schwarting A., Okada M. et al. Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus: a fifty-two-week randomized, double-blind, placebo-controlled study. Arthritis Rheumatol. 2017; 69 (5): 1016–27. DOI: 10.1002/art.40049
- Sohrabian A., Parodis I., Carlstromer-Berthen N. et al. Increased levels of anti-dsDNA antibodies in immune complexes before treatment with belimumab associate with clinical response in patients with systemic lupus erythematosus. Arthritis Res Ther. 2019; 21 (1): 259. DOI: 10.1186/s13075-019-2056-y
- Teng Y.K.O., Bruce I.N., Diamond B. et al. Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol. BMJ Open. 2019; 9 (3): e025687. DOI: 10.1136/bmjopen-2018-025687
- Touma Z., Sayani A., Pineau C.A. et al. Belimumab use, clinical outcomes and glucocorticoid reduction in patients with systemic lupus erythematosus receiving belimumab in clinical practice settings: results from the OBSErve Canada study. Rheumatol Int. 2017; 37 (6): 865–73. DOI: 10.1007/s00296-017-3682-9
- von Kempis J., Duetsch S., Reuschling N. et al. Clinical outcomes in patients with systemic lupus erythematosus treated with belimumab in clinical practice settings: a retrospective analysis of results from the OBSErve study in Switzerland. Swiss Med Wkly. 2019; 149: w20022. DOI: 10.4414/smw.2019.20022